Editorial Comment on “Current Treatment Patterns and Outcomes of Sex Cord Stromal Tumor Patients in Japan”

Sex cord–stromal tumors (SCSTs) of the testis are rare, accounting for approximately 5% of all testicular tumors [1]. The major subtypes are Leydig cell and Sertoli cell tumors. Most present as intrascrotal masses confined to the testis and are clinically benign [2], although about 10% develop metastatic disease [1]. Histopathological risk factors for metastasis have been described [3], but systemic treatment remains undefined, with variable responses to chemotherapy and radiotherapy. Curative treatment for metastatic disease largely relies on complete surgical resection. Owing to their rarity, particularly in Asian populations, the natural history, prognostic factors, and optimal management remain poorly defined, and treatment decisions are often extrapolated from testicular germ cell tumor paradigms despite important biological differences. In this context, Abe et al. reported a nationwide multicenter study providing important insight into the contemporary management of testicular SCSTs in Japan [4]. Through collaboration among 66 institutions, the authors assembled a cohort of 112 patients, representing the largest series reported in Japan. A major strength of the study is the centralized pathological review performed by expert uropathologists in most cases. Several clinically relevant findings emerged. First, the study clarifies clinical presentation: although scrotal enlargement or testicular induration was the most common symptom, a notable proportion of tumors were incidentally detected during infertility evaluation, possibly reflecting increased imaging in reproductive medicine. Second, cumulative pathological risk factors were strongly associated with prognosis in stage I disease, with patients harboring more than two adverse factors showing markedly worse recurrence-free survival. This underscores the value of pathological risk stratification after orchiectomy and the need for careful surveillance in high-risk patients. Third, the study provides insight into recurrence patterns; although relapse sites resembled those of germ cell tumors, some recurrences occurred more than 5 years after treatment, suggesting the need for long-term follow-up. Management of advanced disease remains challenging. Patients with synchronous metastases have poor survival and limited response to germ cell tumor–based chemotherapy. In contrast, durable control after repeated resection in metachronous recurrence suggests a role for aggressive surgery in limited metastatic disease. Thus, retroperitoneal lymph node dissection (RPLND), particularly for stage I patients with multiple pathological risk factors, may be considered. In selected high-risk patients, laparoscopic nerve-sparing RPLND may be a reasonable option with potentially reduced morbidity [5]. Although the retrospective design and treatment heterogeneity are limitations, collaborative studies remain essential in rare diseases where prospective trials are difficult. This nationwide study advances our understanding of SCSTs and represents an important step toward more evidence-based management of this rare tumor. This research was supported by the Japan Society for the Promotion of Science KAKENHI (grant number 25K02772). The author declares no conflicts of interest. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.